ArticleCureus2024
An Uncommon Encounter: Metastatic Olfactory Neuroblastoma in an Adult Male.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory neuroblastoma is an extremely rare malignancy of the sinonasal tract. It is a neuroectodermal tumor, originating from the olfactory epithelium of the nasal and sinus cavities. Due to its rarity, no standard of care treatments have been established to date. We present a case involving a young adult who presented for evaluation of a palpable cervical lymph node. Nasal endoscopy and Magnetic Resonance Imaging (MRI) of the visceral cranium showed a space-occupying lesion in the right nasal cavity, along with a suspicious right submandibular lymph node block. Fine Needle Biopsy (FNB) of the cervical lymph node was suggestive of a small round blue cell tumor, confirming the diagnosis of olfactory neuroblastoma. Staging Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) scan identified multiple bone-lytic metastases. The patient was treated with three lines of systemic therapy, but unfortunately, he succumbed to his disease. This case aims to highlight the intricacies of diagnosing and treating one of the rarest malignancies of the head and neck, particularly in the metastatic setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.